A novel technique for treating GBM first underwent a phase 1 clinical trial with patients who had recurrence of their cancers ...

The glioblastoma multiforme (GBM) treatment market size is on a steep growth trajectory, rising from $2.73 billion in 2025 to ...

Growing progress in vaccination: New approaches for the treatment of glioblastoma have recently been made possible by the quick advancements in immunotherapy. The injection of foreign antigens and ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted orphan drug designation to WP1122 for the treatment of glioblastoma multiforme, according to a ...

A study led by Nicolas Bazan, MD, Ph.D., Boyd Professor and Director of LSU Health New Orleans Neuroscience Center of Excellence, reports that in an experimental model of glioblastoma multiforme (GBM) ...

Glioblastoma multiforme (GBM) is the most common and aggressive type of tumor arising from star shaped cells called as astrocytes that make up supportive tissue of the brain. GBM has long baffled ...

Glioblastoma multiforme is the most common malignant primary brain tumor in adults. Mean progression-free survival is just over 6 months; treatment with surgical resection, chemotherapy, and radiation ...

Please provide your email address to receive an email when new articles are posted on . LP-184 (Lantern Pharma) is a next-generation alkylating agent designed to preferentially damage DNA in cancer ...